development and evaluation under a research collaboration.

**Potential Commercial Applications**

- Novel therapeutics for neurodegenerative diseases AND other indications which involve c-Abl kinase (e.g., lysosomal storage disorders, cancers, etc.).

**Competitive Advantages**

- Novel compounds that have a commercial advantage over those currently known because they are able to selectively bind to c-Abl at an allosteric site, can cross the blood-brain barrier, and show robust efficacy in several neurodegenerative models. All of this allows them to potentially treat neurodegenerative diseases, cancer etc.

**Development Stage**

- Pre-Clinical (in vivo validation).

**Inventors**

- Juan Marugan, Marc Ferrer, Noel Southall, Andres Dulcey, Xin Hu, Christopher Dextras, Daniel Talley, Alejandra Alvarez, Silvana Zanlungo.

**Intellectual Property:**


**Licensing Contact:**

- Ami Gadzia, JD, LL.M., CLP, 301–217–6098; amigadzia@nih.gov.

**Dated:**

- September 25, 2018.

**Lillianne M. Portilla Weingarten,**

**Technology Development Coordinator,**

**National Center for Advancing Translational Sciences.**

**[FR Doc. 2018–23616 Filed 10–29–18; 8:45 am]**

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Child Health and Human Development Special Emphasis Panel; NICHD K99 Teleconference Review.

**Date:**


**Time:**

- 2:00 p.m. to 4:00 p.m.

**Agenda:**

- To review and evaluate grant applications.

**Place:**

- National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20894 (Telephone Conference Call).

**Contact Person:**

- Helen Huang, Scientific Review Branch (SRB), DER, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS, 6710B Rockledge Drive, Rm. 2125B, Bethesda, MD 20817, 301–435–8380, helen.huang@nih.gov.

**Name of Committee:**

- National Institute of Child Health and Human Development Special Emphasis Panel; Pediatric Critical Care and Trauma Scientist Development Program (K12) Teleconference Review.

**Date:**

- December 3, 2018.

**Time:**

- 2:00 p.m. to 4:00 p.m.

**Agenda:**

- To review and evaluate grant applications.

**Place:**

- National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

**Contact Person:**

- Helen Huang, Scientific Review Branch (SRB), DER, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS, 6710B Rockledge Drive, Rm. 2125B, Bethesda, MD 20817, 301–435–8380, helen.huang@nih.gov.

**[Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS]**

Dated: October 24, 2018.

**Melanie J. Pantola,**

**Program Analyst, Office of Federal Advisory Committee Policy.**

**[FR Doc. 2018–23614 Filed 10–29–18; 8:45 am]**

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Aging Special Emphasis Panel; Second Stage Review.

**Date:**

- November 19, 2018.

**Time:**

- 8:30 a.m. to 4:00 p.m.

**Agenda:**

- To review and evaluate contract proposals.

**Place:**

- National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892.

**Contact Person:**

- Kimberly Firth, Ph.D., National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7702, firthkm@mail.nih.gov.

**[Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS]**

Dated: October 24, 2018.

**Ronald J. Livingston, Jr.,**

**Program Analyst, Office of Federal Advisory Committee Policy.**

**[FR Doc. 2018–23614 Filed 10–29–18; 8:45 am]**

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Ancillary Studies Application Review.

**Date:**

- November 2, 2018.

**Time:**

- 12:00 p.m. to 5:00 p.m.

**Agenda:**

- To review and evaluate grant applications.